Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

Long-Acting Injectable Preferred for HIV Preexposure Prophylaxis

admin by admin
February 12, 2023
in News


FRIDAY, Feb. 10, 2023 (HealthDay News) — Long-acting injectable preexposure prophylaxis (PrEP) is the preferred HIV prevention choice for potential male users, according to a study published online Jan. 21 in AIDS and Behavior.

Lorraine T. Dean, Sc.D., from the Johns Hopkins University Bloomberg School of Public Health in Baltimore, and colleagues conducted a discrete choice experiment on preferences for PrEP among 688 gay, bisexual, and other men who have sex with men. Mode of administration, side effects, monetary cost, and time cost were assessed.

The researchers found that long-acting injectable PrEP was preferred, despite mode of administration being the least important PrEP attribute. The most important attribute influencing preferences for PrEP was side effects (44 percent of decision), while costs were the second most important factor (35 percent of decision). The most important preference was for PrEP with no side effects followed by monthly out-of-pocket costs of $0.

“The overall most preferred combination of attributes was PrEP that cost $0 out-of-pocket per month, 30 min travel time, had no side effects, and was administered by injection every few months,” the authors write. “Practitioners and policymakers looking to increase PrEP uptake should keep costs low, communicate clearly about PrEP side effects, and allow the use of patient-preferred modes of PrEP administration, including long-acting injectable PrEP.”

Abstract/Full Text

Copyright © 2023 HealthDay. All rights reserved.
healthday



Source link

Advertisement Banner
Previous Post

Kaiser Permanente posted $4.47B net loss in 2022 as costs rose

Next Post

Without Truth, Progress Is An Impossibility – The Health Care Blog

Related Posts

News

#VisualAbstract: Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa

March 26, 2023
News

Over-the-Scope Clip Beneficial for Nonvariceal Upper GI Bleeding

March 25, 2023
News

Patients with Burns and a Multimodal Pain Management Approach

March 24, 2023
News

Insights from Normalization Process Theory

March 23, 2023
News

Transdermal Testosterone Pretreatment Improves Live Birth Rates in Poor Responders

March 22, 2023
News

Ph-positive Acute Lymphoblastic Leukaemia Treated with Ponatinib and Blinatumomab

March 21, 2023
Next Post

Without Truth, Progress Is An Impossibility – The Health Care Blog

Recommended

Centene to sell Magellan Specialty Health to Evolent Health

4 months ago

Suctioning and Airway Management for Asthmatic Patients

3 months ago

Steps to Earn a Legal Nurse Consultant Certification in 2023

2 months ago

Modern Healthcare’s top 10 engaging stories of 2022

3 months ago

38+ Unique Gifts for Nurses In 2023

3 months ago

© 2022 Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.